Antagonism of pancuronium neuromuscular blockade in halothane-anesthetized ponies using neostigmine and edrophonium.

The research investigates the efficacy of two drugs, neostigmine and edrophonium, in counteracting the effects of the muscle relaxant pancuronium in ponies under halothane anesthesia. The study finds both drugs effective but edrophonium acts faster and has fewer side effects than neostigmine.

Study Design and Findings

• The research focused on evaluating the effectiveness of two antagonistic drugs, neostigmine and edrophonium, used to counteract the effects of pancuronium neuromuscular blockade in ponies anesthetized with halothane.
• Both neostigmine and edrophonium were given to the ponies in respective doses of 0.04 mg/kg of body weight and 1 mg/kg, and their action was observed and compared.
• The study found that both drugs served as satisfactory antagonists to pancuronium, albeit with differences in their onset of action and observable side-effects.
• Significantly, edrophonium showed a quicker onset of action when compared to neostigmine.

Evaluation of Muscarinic Activity

• The muscarinic activity, which refers to the effects of these drugs on the parasympathetic nervous system, of both neostigmine and edrophonium was also scrutinized in the study.
• Specific side-effects such as changes to gastrointestinal function, heightened salivation, and increased airway secretions were examined as part of this.
• The results indicated that these side-effects were considerably minimized with edrophonium, while markedly present on administration of neostigmine.

Effects on Blood Pressure and Heart Rate

• The findings showed an increased blood pressure in the ponies within 1 to 2 minutes of administering either of the antagonist drugs.
• The effect on the heart rate, however, varied depending on the drug. Following the administration of edrophonium, a decrease in heart rate was observed but this occurred after the increase in blood pressure.
• On the other hand, the heart rate either increased or remained unchanged following the administration of neostigmine.